Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Biofrontera Pharma GmbH on +49 214 876 32 66 or Ameluz@biofrontera.com
Biofrontera Biofrontera
  1. Home
  2. About Biofrontera

About Biofrontera

Biofrontera is a biopharmaceutical company specialising in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin.

The company's lead products are Ameluz® (5-aminolaevulinic acid 78 mg/g gel), a topical prescription drug, and a proprietary red-light lamp BF-RhodoLED® for photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is one of the first German biopharmaceutical companies to receive a centralized European and a US-approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard).

 

 

 

 

 

 

Item Number UKBF-2022-006p-V01, Date of preparation: September 2022